A Multicenter, Randomized, Comparison, Open-label, Phase IV Study to Assess the Efficacy and Safety of Advagraf Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients
Phase of Trial: Phase IV
Latest Information Update: 05 Dec 2018
Price : $35 *
At a glance
- Drugs Tacrolimus (Primary) ; Corticosteroid
- Indications Renal transplant rejection
- Focus Pharmacodynamics
- Acronyms COSMOS
- Sponsors Astellas Pharma
- 26 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 04 Nov 2015 Planned End Date changed from 1 Sep 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
- 04 Nov 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.